The Day In Review: Targeted Genetics Corporation Soars While Biotech Falls

November 27, 2006 -- Targeted Genetics climbed over 50% without releasing any news; Mayne bought the ex-US rights to Nipent from SuperGen; the FDA accepted as complete a response from Oscient about pneumonia drug Factive; Cytogen was awarded a patent for its oral drug delivery agents; MannKind received an FDA go-ahead to begin a Phase I clinical trial of its cancer drug; Memory Pharma completed enrollment in a Phase IIa trial of its mania treatment; and Genzyme began dosing older patients in a Phase II trial of its leukemia drug, Clolar. The Centient Biotech 200™ lost 54 points to end at 3930, a drop of 1.35% among a general market pullback. More details...